

,



,



,



,

or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof.

51. A pharmaceutical composition comprising an effective amount of a compound of claim 1, 29, 30, 31, or 50, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.

~~52. Use of a compound of claim 1, 29, 30, 31, or 50, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof for use in the manufacture of a medicament for inhibiting a kinase in a cell expressing said kinase.~~

~~53. The use of claim 52, wherein the kinase is one or more of JNK1 or JNK2.~~

~~54.~~52. Use of a compound of claim 1, 29, 30, 31, or 50 in the manufacture of a medicament for treatment or prevention of liver fibrotic-disorders, or diabetes or metabolic syndrome leading to liver fibrotic disorders.

~~55.~~53. The use of claim 52~~54~~, wherein the liver fibrotic disorder is non-alcoholic steatohepatitis, steatosis, cirrhosis, primary sclerosing cholangitis, primary biliary cirrhosis, hepatitis, hepatocellular carcinoma, or liver fibrosis coincident with chronic or repeated alcohol ingestion, with infection, with liver transplant, or with drug induced liver injury.

~~56.~~54. The use of claim 52~~54~~, wherein the liver fibrotic disorder is non-alcoholic steatohepatitis, steatosis, hepatitis, or cirrhosis.